Controversies at the Cutting Edge of AKI
October 25, 2020 | 02:30 PM - 04:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Clinical Practice Session
Controversies at the Cutting Edge of AKI
October 25, 2020 | 02:30 PM - 04:30 PM
Location: Live-Streamed
Session Description
This session features a diverse set of lectures, each touching on a contemporary controversy in the field of AKI.
Learning Objective(s)
- Describe the limitations of designating all increases in serum creatinine as AKI
- Explain the epidemiology of contrast-induced AKI and strategies for its prevention
- Discuss the status of AKI biomarkers and how they may shape clinical practice
- Appraise the benefits of balanced crystalloids in the prevention of AKI among hospitalized patients
Learning Pathway(s)
Moderators
- Josee Bouchard, MD
- Raymond K. Hsu, MD
Presentations
- Much Ado About Nothing: Should All Increases in Serum Creatinine Cause Us to Worry?
02:30 PM - 03:00 PM
Steven G. Coca, DO, MS
Steven G. Coca, DO, MS
Steven G. Coca, DO, is a graduate of the University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in Connecticut. He also received a Master’s Degree in Epidemiology and Public Health during his training at Yale. There, he later served as an Assistant Professor in the Section of Nephrology, until his recruitment to Mount Sinai in 2014 as Associate Professor. He is the Director for Clinical Research for the Division of Nephrology and is the Associate Chair for Clinical and Translational Research for the Department of Medicine at the Icahn School of Medicine at Mount Sinai.
His research has focused on using novel biomarkers to improve risk stratification in patients with acute kidney injury and patients at risk or with prevalent chronic kidney disease. He has been continually funded by the NIH over the last decade for multiple biomarker-related projects. He is the co-founder of RenalytixAI.
Much Ado About Nothing: Should All Increases in Serum Creatinine Cause Us to Worry?
October 25, 2020 | 02:30 PM - 03:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Biomarkers in AKI: Will They Ever Be Ready for Prime Time?
03:00 PM - 03:30 PM
Sherry Mansour, MD, MS
Biomarkers in AKI: Will They Ever Be Ready for Prime Time?
October 25, 2020 | 03:00 PM - 03:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Does Contrast-Induced AKI Exist, and If It Does, How Can We Prevent It?
03:30 PM - 04:00 PM
Steven D. Weisbord, MD, FASN
Steven D. Weisbord, MD, FASN
Does Contrast-Induced AKI Exist, and If It Does, How Can We Prevent It?
October 25, 2020 | 03:30 PM - 04:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Balanced Crystalloid Solutions: The New Standard of Care in Hospitalized Patients?
04:00 PM - 04:30 PM
Edward D. Siew, MD, MS
Edward D. Siew, MD, MS
Edward D. Siew is an Associate Professor of Medicine in the Division of Nephrology at the Vanderbilt University Medical Center and the Nashville Veterans Affairs Hospital Nashville, TN. Dr. Siew received his medical degree at the University of Chicago Pritzker School of Medicine and completed his residency in internal medicine at The University of California, San Francisco. He also completed fellowships in Critical Care Medicine and the University of Pittsburgh School of Medicine and Nephrology at Vanderbilt University School of Medicine. Dr. Siew's research program is focused on improving the care of patients with acute kidney injury (AKI). Ongoing projects include using novel biomarkers of injury to refine the diagnosis of AKI and provide better prognostic information, leveraging the electronic health record to better examine healthcare delivery to patients who experience AKI,improving understanding of the long-term impact of this disease, and clinical trials for the prevention and treatment of AKI.
Balanced Crystalloid Solutions: The New Standard of Care in Hospitalized Patients?
October 25, 2020 | 04:00 PM - 04:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
